Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 287 clinical trials
Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis

Metastatic colorectal cancer is one of the common malignant tumors and the overall prognosis is poor. The introduction of immune-checkpoint inhibition (ICI) has led to a paradigm shift in the treatment of patients with metastatic cancer. Stereotactic body radiation therapy (SBRT) delivers a large dose of radiation to the tumor …

cytokines
solid tumour
metastasis
  • 0 views
  • 23 Jan, 2021
  • 1 location
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab, or atezolizumab), physicians' choice chemotherapy plus pembolizumab (or placebo) will be administered (3 weeks per cycle) until disease progression or unacceptable toxicity.

carcinoma
systemic therapy
nivolumab
measurable disease
pd-l1
  • 13 views
  • 23 Jan, 2021
  • 1 location
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate), six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.

  • 1 views
  • 26 Jan, 2021
  • 3 locations
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

This is a randomized, multi-center, double-blind, Phase III study of radium-223 plus enzalutamide or darolutamide compared to enzalutamide or darolutamide treatment plus placebo.

other imaging modalities
bisphosphonate
androgen
bone scan
adenocarcinoma
  • 0 views
  • 25 Jan, 2021
  • 1 location
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.

  • 0 views
  • 26 Jan, 2021
  • 6 locations
Metastasis-directed Therapy in Castration-refractory Prostate Cancer

The aim is to define the postponement of next line systemic treatment (NEST), by the use of metastasis-directed therapy in patients with oligoprogressive castration-refractory prostate cancer. This will be defined by the NEST-free survival. Furthermore the investigators will use 18F PSMA PET-CT as investigational imaging, to assess the predictive value …

pet/ct
docetaxel
adenocarcinoma
adenocarcinoma of prostate
abiraterone
  • 0 views
  • 23 Jan, 2021
TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.

EGFR
  • 0 views
  • 23 Jan, 2021
  • 1 location
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

This is an open-label, multicenter, non-randomized Phase 1b clinical trial for patients with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous NSCLC, RCC, OC, or melanoma.

  • 70 views
  • 25 Jan, 2021
  • 16 locations
Intermittent Selumetinib for Uveal Melanoma

The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the drug Selumetinib will have on subjects with uveal melanoma. Selumetinib is a drug that blocks (or turns off) methyl ethyl ketone (MEK), a protein activated in some uveal melanoma cells. Selumetinib is …

liver disease
spiral ct scan
measurable disease
mek inhibitor
karnofsky performance status
  • 0 views
  • 23 Jan, 2021
  • 2 locations
OMEGA Local Ablative Therapy in Oligometastatic NSCLC

Oligometastatic lung cancer (OM-NSCLC) seems to be associated with a better prognosis than usual Stage IV non-small cell lung cancer when radical local therapy of all metastatic sites is administered but the impact of such an approach on overall survival and quality of life remains to be defined by adequately …

brain metastases
EGFR
ct scan
lung carcinoma
platinum doublet
  • 0 views
  • 23 Jan, 2021
  • 1 location